Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
3 hedge funds and large institutions have $2.41K invested in Lixte Biotechnology Warrants in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0.98% less ownership
Funds ownership: 3.84% → 2.86% (-0.98%)
43% less capital invested
Capital invested by funds: $4.27K → $2.41K (-$1.85K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$13 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $1.53K | – | – | – |
|
|
CS
2
Clear Street
New York
| $872 | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $8 | +$13 | +210 | New |
|
LIXTW Hedge Fund Activity: Q4 2023 in Review
3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q4 2023, worth a combined $2.41K — down 43% from $4.27K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new LIXTW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $13.
- 3 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q4 2023, up from 2 in Q3 2023.
- Funds reported $2.41K of Lixte Biotechnology Warrants stock for Q4 2023, down 43% quarter-over-quarter.
- 1 fund opened new Lixte Biotechnology Warrants positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest Lixte Biotechnology Warrants buyer in Q4 2023 was UBS Group, an estimated $13 added.
Based on aggregated 13F filings for Q4 2023.